Your browser doesn't support javascript.
loading
Prevalence of germline MUTYH mutations among Lynch-like syndrome patients.
Castillejo, Adela; Vargas, Gardenia; Castillejo, María Isabel; Navarro, Matilde; Barberá, Víctor Manuel; González, Sara; Hernández-Illán, Eva; Brunet, Joan; Ramón y Cajal, Teresa; Balmaña, Judith; Oltra, Silvestre; Iglesias, Sílvia; Velasco, Angela; Solanes, Ares; Campos, Olga; Sánchez Heras, Ana Beatriz; Gallego, Javier; Carrasco, Estela; González Juan, Dolors; Segura, Angel; Chirivella, Isabel; Juan, María José; Tena, Isabel; Lázaro, Conxi; Blanco, Ignacio; Pineda, Marta; Capellá, Gabriel; Soto, José Luis.
Afiliação
  • Castillejo A; Molecular Genetics Laboratory, Elche University Hospital, Elche, Alicante, Spain.
  • Vargas G; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Castillejo MI; Molecular Genetics Laboratory, Elche University Hospital, Elche, Alicante, Spain.
  • Navarro M; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Barberá VM; Molecular Genetics Laboratory, Elche University Hospital, Elche, Alicante, Spain.
  • González S; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Hernández-Illán E; Laboratory of Investigation, Alicante University Hospital, Alicante, Spain.
  • Brunet J; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IdIBGI, Girona, Spain.
  • Ramón y Cajal T; Medical Oncology Service, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
  • Balmaña J; University Hospital of Vall d'Hebron, Barcelona, Spain.
  • Oltra S; Genetics Department, La Fe University Hospital, Valencia, Spain.
  • Iglesias S; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Velasco A; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IdIBGI, Girona, Spain.
  • Solanes A; Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, Barcelona, Spain.
  • Campos O; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Sánchez Heras AB; Genetic Counselling in Cancer, Hereditary Cancer Program, Elche University Hospital, Elche, Alicante, Spain; Department of Medical Oncology, Elche University Hospital, Elche, Alicante, Spain.
  • Gallego J; Department of Medical Oncology, Elche University Hospital, Elche, Alicante, Spain.
  • Carrasco E; Vall d́Hebron Institute of Oncology, Barcelona, Spain.
  • González Juan D; Medical Oncology Service, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
  • Segura A; Genetic Counselling in Cancer, Hereditary Cancer Program, La Fe University Hospital, Valencia, Spain.
  • Chirivella I; Genetic Counselling in Cancer, Hereditary Cancer Program, Clinical University Hospital of Valencia, Valencia, Spain.
  • Juan MJ; Genetic Counselling in Cancer, Hereditary Cancer Program, Valencian Institute of Oncology, Valencia, Spain.
  • Tena I; Genetic Counselling in Cancer, Hereditary Cancer Program, Provincial Hospital of Castellón, Castellón, Spain.
  • Lázaro C; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Blanco I; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain; Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, Barcelona, Spain.
  • Pineda M; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Capellá G; Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.
  • Soto JL; Molecular Genetics Laboratory, Elche University Hospital, Elche, Alicante, Spain. Electronic address: soto_jos@gva.es.
Eur J Cancer ; 50(13): 2241-50, 2014 Sep.
Article em En | MEDLINE | ID: mdl-24953332
BACKGROUND AND AIMS: Individuals with tumours showing mismatch repair (MMR) deficiency not linked to germline mutations or somatic methylation of MMR genes have been recently referred as having 'Lynch-like syndrome' (LLS). The genetic basis of these LLS cases is unknown. MUTYH-associated polyposis patients show some phenotypic similarities to Lynch syndrome patients. The aim of this study was to investigate the prevalence of germline MUTYH mutations in a large series of LLS patients. METHODS: Two hundred and twenty-five probands fulfilling LLS criteria were included in this study. Screening of MUTYH recurrent mutations, whole coding sequencing and a large rearrangement analysis were undertaken. Age, sex, clinical, pathological and molecular characteristics of tumours including KRAS mutations were assessed. RESULTS: We found a prevalence of 3.1% of MAP syndrome in the whole series of LLS (7/225) and 3.9% when only cases fulfilling clinical criteria were considered (7/178). Patients with MUTYH biallelic mutations had more adenomas than monoallelic (P=0.02) and wildtype patients (P<0.0001). Six out of nine analysed tumours from six biallelic MUTYH carriers harboured KRAS-p.G12C mutation. This mutation was found to be associated with biallelic MUTYH germline mutation when compared with reported series of unselected colorectal cancer cohorts (P<0.0001). CONCLUSIONS: A proportion of unexplained LLS cases is caused by biallelic MUTYH mutations. The obtained results further justify the inclusion of MUTYH in the diagnostic strategy for Lynch syndrome-suspected patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prevalence_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2014 Tipo de documento: Article